Ensign Peak Advisors
MCRB icon

Ensign Peak Advisors’s Seres Therapeutics MCRB Stock Holding History

Ensign Peak Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,539
Closed -$198K – 2037
2022
Q3 		$198K Hold
1,539
– – ﹤0.01% 1881
2022
Q2 		$106K Hold
1,539
– – ﹤0.01% 1950
2022
Q1 		$219K Hold
1,539
– – ﹤0.01% 1854
2021
Q4 		$256K Buy
+1,539
New +$245K ﹤0.01% 1868

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ensign Peak Advisors's MCRB Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 1,539 shares — an estimated $198K sold.

Ensign Peak Advisors first reported a position in MCRB in Q4 2021 and held it in 4 quarters. The position peaked at $256K in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,539 Seres Therapeutics shares in Q4 2022, an estimated $198K.
  • Ensign Peak Advisors first reported a position in Seres Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Seres Therapeutics position peaked at $256K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.